US Pulmonary Function Testing Systems Market

US Pulmonary Function Testing Market Research Report Information by Type (Complete PFT Systems and Portable PFT Systems), Test Type (Spirometry, Lung Volume, Gas Exchange Testing, Maximal Voluntary Ventilation, Oxygen Titration Test and High Altitude Simulation Testing), Component (Software, Hardware and Services), Application (Chronic Obstructive Pulmonary Disease, Asthma, Chronic Shortness of Breath and Restrictive Lung Disease), End User (Hospital/Clinical Laboratories and Diagnostics Laboratories) and Region (Americas, Europe, Asia-Paci

ID: MRFR/LS/11207-US | 100 Pages | Author: MRFR Research Team | December 2023         

Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid

The Americas serve as a significant domain for the pulmonary function testing (PFT) market, partitioned primarily into North America and South America, with North America encompassing the United States and Canada. The dominance of the Americas in the global market can be attributed to the burgeoning technological strides in diagnostic tools and the escalating incidence of respiratory ailments and pulmonary disorders. Within this region, the United States stands as the frontrunner, holding the lion's share in the pulmonary function testing sector.

Several pivotal factors contribute to the burgeoning growth of this market, particularly the upsurge in the prevalence of lung cancer and various chronic respiratory conditions. Notably, the statistics furnished by the Asthma and Allergy Foundation of America depict the significant impact of asthma on healthcare. In the US alone, asthma results in about 9.8 million doctor’s office visits, nearly 189,000 hospital inpatient discharges, and a staggering 1.8 million emergency department visits annually.

The American Respiratory Labs, in 2016, conducted diverse respiratory evaluations mandated by Medicare. These assessments encompassed blood oxygen saturation tests, crucial for determining eligibility for supplemental oxygen, and capnography to monitor exhaled carbon dioxide levels, a crucial measure in averting respiratory failure in patients under certain pain medications. One of the most potent tests for predicting survival in chronic obstructive pulmonary diseases (COPD) is the diffusing capacity of the lungs for carbon monoxide (DLCO). NDD Medical Technologies, a pioneer in spirometry, devised a compact yet comprehensive pulmonary function testing device called EasyOne Pro. This innovative apparatus facilitates DLCO testing, spirometry, and complete lung volume assessments within a mere 20 minutes, irrespective of the location. With a commanding 40% share in the US spirometry market, NDD Medical Technologies offers user-friendly and groundbreaking pulmonary function testing solutions.

The technological advancements and the introduction of sophisticated devices like EasyOne Pro signify the progressive trajectory of pulmonary function testing. These cutting-edge innovations not only expedite the diagnostic process but also provide enhanced capabilities in disease prognosis and patient management. Such advancements are instrumental in transforming the landscape of respiratory healthcare by offering versatile, efficient, and easy-to-operate testing tools, ultimately ensuring more accurate and timely interventions for patients with pulmonary disorders.